They showed that scientists in Qatar produced 18. 1 patients with diabetic neuropathy per million people.
Doha – An independent study into findings on diabetes-related nerve damage has identified Qatar as the second most productive country in the world, relative to the length of its population.
The study, published in the journal Frontiers in Endocrinology, showed that scientists in Qatar produced 18. 1 patients in diabetic neuropathy compared to millions of people (51 patients; 2. 83 million people), in Denmark alone, which produced 20. 27 patients compared to millions of people. other people (117 million people). Articles; 5. 77 million inhabitants).
Dr. Rayaz Malik, Professor of Medicine and Associate Dean of Clinical Research at WCM-Q, has been involved in most of the published studies that led Qatar to the highest ranking.
Dr Malik, who last year was ranked as the number one medical researcher in Qatar through Research. com, an independent study portal that compiles a global list of high-performing scientists each year, said: “It is incredibly gratifying to see independent researchers in biomedical studies, especially on diabetes, it has a global impact. Diabetic neuropathy can lead to severe pain, foot ulcers, and amputations in other people with diabetes. Therefore, it is wonderful to see that Qatar makes a great contribution to studies in this area.
The study, titled “The Landscape of Global Studies on Diabetic Neuropathy,” was published by researchers at the University of Exeter in the United Kingdom and Goethe University in Frankfurt, Germany.
The study paper also shows that Qatar is the third most productive country in diabetic neuropathy studies relative to gross domestic product (GDP), Denmark (first) and the United Kingdom (second), and ahead of clinical heavyweights such as the United States (fourteenth). . Germany (11th), Switzerland (10th), Canada (8th) and the Netherlands (6th). The study also revealed Dr. Malik’s strong foreign collaboration between Qatar and the United Kingdom, one of the world’s leading countries in diabetes studies.
Dr. Malik, of WCM-Q, is a consultant physician in endocrinology and diabetes at Hamad Medical Corporation (HMC) and pioneered the use of corneal confocal microscopy (CCM), a rapid, non-invasive ophthalmic imaging strategy for diagnosis and waiting. the progression of neurodegenerative diseases in patients with diabetic neuropathy, long COVID, Parkinson’s disease, sclerosis, dementia, schizophrenia, and autism, among others.
To read the full article in Frontiers in Endocrinology, https://www. frontiersin. org/journals/endocrinology/articles/10. 3389/fendo. 2023. 1220896/complete
About Weill Cornell Medicine-Qatar
Weill Cornell Medicine-Qatar is a partnership between Cornell University and the Qatar Foundation. It offers a comprehensive six-year medical program leading to the medical degree from Cornell University with instruction taught by Professors Cornell and Weill Cornell and physicians from Hamad Medical Corporation (HMC). , Aspetar Orthopaedic and Sports Medicine Hospital, Primary Health Care Corporation, Feto. Maternal Center and Sidra Medicine, which have appointments with Weill Cornell. Through its biomedical studies program, WCM-Q is building a network of sustainable studies in Qatar while advancing fundamental science and clinical studies. Through its Faculty of Medicine, WCM-Q seeks to provide the most productive education imaginable for medical students, improve healthcare now and for future generations, and provide high-quality healthcare to the people of Qatar.
For more info, please contact: Hanan Lakkis Associate Director, Media and Publications Weill Cornell Medicine – Qatar [email protected]
Disclaimer: The content of this press release was provided through a third-party vendor. This online page is not responsible for this external content and does not do so. This content is provided on an “as is” and “as available” basis and has not been modified in any way. Neither this website nor our affiliates guarantee the accuracy or endorse the views or reviews expressed in this press release.
The press release is provided for informational purposes only. The Content does not provide tax, legal, or investment recommendations or reviews relating to the suitability, value, or profitability of any specific security, portfolio, or investment strategy. Neither this nor our affiliates will be liable for any errors or inaccuracies in the content. , or by any movement made through you in reaction to it. You expressly agree that the use of data in this segment is at your own risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.